Refine by
Brain Disease Articles & Analysis: Older
29 news found
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine ...
Kurve’s device is designed to deliver medication directly to the brain with disease-modifying clinical success and enhanced efficacy — while avoiding systemic side effects. Bypassing the blood-brain barrier (BBB) and nose-to-brain delivery have long been the elusive “holy grail” for the treatment of CNS ...
Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track Designation, as it recognizes the evidence demonstrating the potential for UB-311 to address a serious unmet medical need for patients with Alzheimer’s disease,” said Mei Mei Hu, Chief Executive Officer ...
ByVaxxinit
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. ...
“Our research is exciting because while other devices require surgery that involves opening the skull, this brain-computer interface device is much less invasive. It receives electrical signals from the brain, allowing people to control a computer by ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other ...
Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an ...
2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. ...
” Survival analysis is a game-changer for a diverse variety of disciplines and areas of research Most experts, however, mistakenly consider survival analysis a tool solely applied to study death and disease, an accurate method to measure relapse of a medical condition, the potential hospitalization of a patient, and the mortality rate in medicine and biomedical ...
ByJADBio
Brain-assessment device innovator BrainScope, and Aon plc (NYSE: AON), a leading global professional services firm, today announced the completion of an intellectual property-based funding arrangement. ...
This project, led by Oxford Brain Diagnostics and Dr Nakajima, will gather real world MRI patient data, and will use CDM analysis, based on changes at the cellular level, to assess dementia disease severity and potentially support differential diagnosis. ...
Liver Transplant India is generally recommended if you have a last-stage liver disease, which is chronic liver failure. This is a life-threatening and serious liver disease, and this is be caused by many liver conditions. For instance, cirrhosis is one of the common causes of end-stage liver disease. It is one of the chronic liver ...
The Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System) is a Brain-Computer-Interface (BCI) device that assists in rehabilitation for stroke patients with upper extremity—or hand, wrist and arm—disability. ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. ...
BrainScope, a medical neurotechnology company that is a pioneer in the use of A.I. and machine learning in the creation of biomarkers of brain injuries and disease was selected from five finalists as the company with the most commercial potential at the 5th Annual BioHealth Capital Region Crab Trap Competition. The Bethesda, Maryland based company is helping ...
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of ...
In her new role, Hertzberg will drive the global strategy and commercialization of BrainScope’s traumatic brain injury (TBI) and concussion tools in the traditional healthcare, military and sports arenas and will expand the platform capabilities of its signature product Brainscope One to include objective assessments for brain diseases like ...
Amyloid PET is the standard method for the detection of amyloid plaques in the brain, a key hallmark of Alzheimer's disease, and may be useful to confirm the diagnosis and optimize the patient management of patients being evaluated of Alzheimer's disease and other causes of cognitive decline. ...